c-kit Mutation Analysis, Plasma-based, Leumeta®

The c-kit Mutation Analysis, Plasma-based, Leumeta® test contains 1 test with 1 biomarker.

Activating c-kit mutations have been identified in various human cancers. C-kit exon 8 and 17 mutations have been described in patients with CBF-AMLs and usually confer a poor prognosis with increased relapse rate. C-kit exon 9, 11, 13, 17 mutations have been reported in nearly 90% of GIST patients. The presence mutation usually predicts poor survival. C-kit exon 17 mutation has been reported in patients with systemic mastocytosis.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: ckit Mutation Analysis Plasmabased Leumeta

C Kit Mutation Analysis,